A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
| Autor: | Abdul Razak, A.R., Soulières, D., Laurie, S.A., Hotte, S.J., Singh, S., Winquist, E., Chia, S., Le Tourneau, C., Nguyen-Tan, P.- F., Chen, E.X., Chan, K.K., Wang, T., Giri, N., Mormont, C., Quinn, S., Siu, L.L. * |
|---|---|
| Zdroj: | In Annals of Oncology March 2013 24(3):761-769 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|